Expertise in
13
conditions

Dr. Darrell E. White

Ophthalmology
Whitestar Professional Corp.
2237 Crocker Rd Ste 100, 
Westlake, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
13
conditions
Whitestar Professional Corp.
2237 Crocker Rd Ste 100, 
Westlake, OH 

Overview

Darrell White is an Ophthalmologist practicing medicine in Westlake, Ohio.

Dr. White is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Dry Eye Syndrome, Cataract, Blepharitis, and Glaucoma.

He is actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 6 clinical trials. Dr. White is currently accepting new patients.

Specialties

Ophthalmology

Licenses

Ophthalmology in OH

Hospital Affiliations

Southwest General Health Center
Fairview Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Dominion National
  • MEDICARE PDP
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Whitestar Professional Corp.
2237 Crocker Rd Ste 100, Westlake, OH 44145

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.
Enrollment Status: Completed
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Busulfan, Melphalan, Lenalidomide
Study Phase: Phase 2
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 1/Phase 2
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 04, 2023
Intervention Type: Biological
Study Drugs: DCdP, DCd+P
Study Phase: Phase 2
View 5 Less Clinical Trials

79 Total Publications

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".
From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".
Journal: Haematologica
Published: July 29, 2026
Similar Doctors
Expertise in
41
conditions
Expertise in
41
conditions
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (16.4 miles away)
216-444-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sunil Srivastava is an Ophthalmologist practicing medicine in Cleveland, Ohio. Dr. Srivastava is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Uveitis, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Srivastava is currently accepting new patients.

Expertise in
33
conditions
Dr. Justis P. Ehlers
Ophthalmology
Expertise in
33
conditions
Dr. Justis P. Ehlers
Ophthalmology
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (16.4 miles away)
216-636-0183
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Justis Ehlers is an Ophthalmologist practicing medicine in Cleveland, Ohio. Dr. Ehlers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Corneal Transplant. Dr. Ehlers is currently accepting new patients.

Expertise in
62
conditions
Expertise in
62
conditions
Referral may be required

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
 (16.3 miles away)
216-444-8950
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elias Traboulsi is an Ophthalmologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 44 years. Dr. Traboulsi is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Stargardt Macular Degeneration, Retinopathy Pigmentary Mental Retardation, Leber Congenital Amaurosis, Cataract Removal, and Vitrectomy. Dr. Traboulsi is currently accepting new patients.

Frequently Asked Questions about Dr. Darrell E. White

How do I make an appointment with Dr. Darrell E. White?

You can book an appointment with Dr. Darrell E. White by calling their office at 440-892-3931. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Darrell E. White a top-rated expert for Dry Eye Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Darrell E. White is classified as an Distinguished expert for Dry Eye Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Darrell E. White specialize in?

While Dr. Darrell E. White is a Ophthalmology, they have specific expertise in Dry Eye Syndrome, Cataract, and Blepharitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Darrell E. White participate in research or clinical trials?

Yes. Dr. Darrell E. White has published 79 articles and abstracts on conditions like Dry Eye Syndrome. You can view a list of Dr. Darrell E. White's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Darrell E. White accept my insurance?

Dr. Darrell E. White accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 440-892-3931 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. White's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile